Merck and Eli Lilly to Report Q3 Results
The pharmaceutical giants are set to release third-quarter earnings reports on October 29, 2026.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Will Merck and Eli Lilly report higher-than-projected earnings for the third quarter of 2026?
Merck and Eli Lilly are scheduled to disclose their third-quarter financial results on October 29, 2026. Analysts anticipate earnings declines for both pharmaceutical companies as they navigate complex market pressures.
Why it matters
Investors are closely monitoring these reports for updates on how Merck manages its patent cliff and how Eli Lilly maintains momentum in the competitive obesity drug sector. Financial performance in these areas will offer key insights into the near-term health of these major industry players.
Analysts project Merck earnings per share to reach $2.09, representing a 19% decline compared to prior expectations. These figures come as the company contends with significant changes in specialty pharmacy purchasing.
The players
Merck
This global pharmaceutical company develops a range of healthcare solutions and faces ongoing challenges regarding its patent portfolio.
Eli Lilly
This major pharmaceutical entity operates as a leader in the development and distribution of weight-loss and obesity medications.
The details
Merck is facing headwinds including a looming patent cliff and slower U.S. sales growth for Keytruda, though generic competition has remained lower than anticipated. Meanwhile, Eli Lilly relies heavily on its Mounjaro and Zepbound obesity and weight-loss franchise to drive growth amid increasing market competition and pricing pressures.
Timeline
Merck and Eli Lilly release their third-quarter results on October 29, 2026.
Market Landscape
These earnings reports arrive as pharmaceutical firms navigate the competitive landscape defined by the Hatch-Waxman Act, which sets the framework for generic market entry. This dynamic forces large companies to aggressively defend their remaining patent-protected franchises.
These financial reports may influence future investment strategies for retail shareholders and could impact long-term pricing for pharmaceutical products. Consumers should watch for how these corporate results affect overall product availability and market competition.
The takeaway
Investors should monitor the guidance provided by management to understand how these companies plan to mitigate current revenue growth hurdles. Identifying shifts in specialty pharmacy purchasing can provide clarity on the sustainability of current drug pricing models.
Further reading
For more on industry performance, see the United States Healthcare sector analysis.
Live Poll
Will Merck and Eli Lilly report higher-than-projected earnings for the third quarter of 2026?
